Published in Medical Devices and Surgical Technology Week, October 5th, 2008
"This patent provides broad coverage of hESC-derived cardiomyocytes for cell therapy and drug screening applications," said David J. Earp, J.D., Ph.D., Geron's senior vice president of business development and chief patent counsel. "The addition of this patent to our robust portfolio of Geron-owned and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week